RT Journal Article
T1 Perpetual observational studies: new strategies to support efficient implementation of observational studies and randomized trials in infectious diseases.
A1 Hassoun-Kheir, Nasreen
A1 van-Werkhoven, C Henri
A1 Dunning, Jake
A1 Jaenisch, Thomas
A1 van-Beek, Janko
A1 Bielicki, Julia
A1 Butler, Christopher C
A1 Francois, Bruno
A1 Harbarth, Stephan
A1 Hernandez Padilla, Ana C
A1 Horby, Peter
A1 Koopmans, Marion
A1 Lee, James
A1 Rodriguez-Baño, Jesus
A1 Tacconelli, Evelina
A1 Themistocleous, Yrene
A1 van-der-Velden, Alike W
A1 Bonten, Marc
A1 Goossens, Herman
A1 de-Kraker, Marlieke E A
K1 Antimicrobial resistance
K1 Emerging infectious diseases
K1 Perpetual observational studies
K1 Research network
K1 Study methodology
AB Emerging infectious diseases are a growing threat, through population growth , increased trade and travel , urbanization , deforestation , and climate change [1]. Clinical research in response to emerging infectious diseases is challenging; selecting and contracting the appropriate study sites for a trial is time consuming, and often too few patients can be timely recruited to acquire high-quality evidence about the best treatment strategies [2]. In 2014, the EU-funded PREPARE project (Platform foR European Preparedness Against (Re-)emerging Epidemics ) was initiated to rapidly respond to severe infectious diseases outbreaks . It initiated two adaptive platform trials, the REMAP-CAP [3] and the ALIC4E trial [4], determining the effectiveness of multiple treatment strategies for a single disease . The REMAP-CAP trial was designed for a pandemic of severe community-acquired pneumonia and expanded globally during the COVID-19 pandemic. It has already delivered 10 important conclusions for better treatment of COVID-19 [3].
PB Elsevier Ltd
YR 2022
FD 2022-12
LK http://hdl.handle.net/10668/22135
UL http://hdl.handle.net/10668/22135
LA en
NO Hassoun-Kheir N, van Werkhoven CH, Dunning J, Jaenisch T, van Beek J, Bielicki J, et al. Perpetual observational studies: new strategies to support efficient implementation of observational studies and randomized trials in infectious diseases. Clin Microbiol Infect. 2022 Dec;28(12):1528-1532.
DS RISalud
RD Aug 6, 2025